Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma

NCT06788964 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT06788964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2025
Completion date
March 31, 2030
Enrollment
29 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory large b-cell lymphoma